CSIMarket


Jazz Pharmaceuticals Plc  (JAZZ)
Other Ticker:  
 

Jazz Pharmaceuticals Plc

JAZZ's Fundamental analysis








Looking into Jazz Pharmaceuticals Plc growth rates, revenue grew by 1.03 % in I. Quarter 2024 from the same quarter a year ago. Ranking at No. 1466

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -0.31 %

Jazz Pharmaceuticals Plc faced net loss in contrast to the net income a year ago in I. Quarter 2024

More on JAZZ's Growth


Jazz Pharmaceuticals Plc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Jazz Pharmaceuticals Plc PEG ratio is at -0.1 Company is currently trading with Price to Cash flow multiple of 24.08 in trailing twelve-month period.
Company
22.88
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.73.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.31.


More on JAZZ's Valuation
 
 Total Debt (Millions $) 5,710
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 2,234,520
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 5.8
 Tangible Book Value (Per Share $) -52.43

Jazz Pharmaceuticals Plc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Jazz Pharmaceuticals Plc PEG ratio is at -0.1 Company is currently trading with Price to Cash flow multiple of 24.08 in trailing twelve-month period.
Company
22.88
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.73.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.31.

Jazz Pharmaceuticals Plc Price to Book Ratio is at 1.79 lower than Indusry Avg. of 74.58. and higher than S&P 500 Avg. of 0.01

More on JAZZ's Valuation

  Market Capitalization (Millions $) 6,633
  Shares Outstanding (Millions) 63
  Employees 1,720
  Revenues (TTM) (Millions $) 3,843
  Net Income (TTM) (Millions $) 331
  Cash Flow (TTM) (Millions $) 275
  Capital Exp. (TTM) (Millions $) -27
  Total Debt (Millions $) 5,710
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 2,234,520
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) 5.8
  Tangible Book Value (Per Share $) -52.43

  Market Capitalization (Millions $) 6,633
  Shares Outstanding (Millions) 63
  Employees 1,720
  Revenues (TTM) (Millions $) 3,843
  Net Income (TTM) (Millions $) 331
  Cash Flow (TTM) (Millions $) 275
  Capital Exp. (TTM) (Millions $) -27


    JAZZ's Profitability Comparisons
Jazz Pharmaceuticals Plc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in I. Quarter 2024 to 7.34 % from 12.11 % in IV. Quarter.







  Ratio
   Capital Ratio (MRQ) 2.27
  Total Debt to Equity (MRQ) 1.54
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.35
  Inventory Turnover Ratio (TTM) -



Jazz Pharmaceuticals Plc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in I. Quarter 2024 to 7.34 % from 12.11 % in IV. Quarter.



More on JAZZ's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com